Atturos Products

In line with our vision, Atturos is committed to developing tests that allow patients and clinicians to make better decisions based on excellent science. 

Blood Test


RAPsA Dx is Atturos' lead product. With its ability to discriminate patients who have rheumatoid arthritis (RA) from those who have psoriatic arthritis (PsA) it is the first molecular diagnostic test (Dx) for the diagnosis of psoriatic arthritis.

The RAPsA Dx test performance of over 90% has been fully evaluated and is described in a recent landmark peer reviewed publication

The RAPsA Dx protein signature is the subject of a patent from University College Dublin (UCD) and is licenced exclusively to Atturos worldwide.


OCPro Dx

OCPro Dx is a multi-protein biomarker blood test for organ confined prostate cancer that gives patients and clinicians clearer information to help them make treatment decisions. Early clinical data supports the continued commercialisation of the product. Atturos is currently assessing plans to commercialise the development strategy for OCPro Dx.

Electronic Circuit


PromarkerD is a blood test to assess the risk of diabetic kidney disease (DKD) in patients with type 2 diabetes. It is a simple blood test that measures a panel of three novel plasma biomarkers combined with 3 clinical factors. The test has been developed by Proteomics International Laboratories Ltd (PILL), a medical technology company headquartered in Perth, Australia. 

Atturos has completed the successful transfer of the PromarkerD method to the Atturos laboratory. We are now working with PILL to assess the commercialisation potential for the PromarkerD test in Europe.